Here we developed an effective therapeutic approach using a replication -conditional mutant of herpes simplex virus ( HSV ), G207, for the treatment of metastatic tumors in the immunologically privileged central nervous system. An experimental model of brain metastasis was developed using BALB / c mice that harbored both intracranial ( i.c. ) and subcutaneous ( s.c. ) mouse CT26 colon adenocarcinoma tumors. Intratumoral injections of G207 into s.c. tumors elicited cytotoxic T -cell responses not only to HSV but also to a tumor antigen; however, only a limited antitumor effect was observed on metastatic brain tumors. To improve this antitumor effect, G207 was also injected into the brain tumor. After intratumoral injections of G207 into both i.c. and s.c. CT26 tumors, a significant antitumor effect was observed in the metastatic brain tumors. This therapeutic efficacy was absent in athymic mice, indicating that the antitumor effect could be mediated by T cells. Cytotoxic T -cell responses to HSV and the tumor antigen were induced by injections of G207 into i.c. and s.c. CT26 tumors. These results suggest that HSV -infected brain tumors may be efficiently eliminated by the induced anti -HSV T cells as well as by antitumor T cells. Therefore, this strategy of immuno -viral therapy, involving direct viral oncolytic activities and inducing antitumor and antiviral immune responses, may be useful for the treatment of tumors in the immunologically privileged central nervous system.
T he central nervous system ( CNS ) is generally considered to be an immunologically privileged site, although increasing evidence of autoimmunity and immunological responses to brain antigens has been recognized. Recent studies have shown that lymphocytes migrate across the blood -brain barrier ( BBB ) into the CNS without any pathological changes. 1, 2 Of the lymphocytes that enter the CNS, only activated T cells specific for CNS antigens cause local immune responses, under special conditions. 3 These observations suggest that brain tumors might be selectively eliminated by T cells activated with specific antigens for brain tumors.
A conditionally replicating herpes simplex virus ( HSV ) vector, G207, has deletions in both copies of the ICP34.5 gene and an inserted Escherichia coli lacZ gene that inactivates the ICP6 gene. 4 Due to these mutations, G207 replicates selectively within tumor cells and causes tumor cell destruction without local or systemic toxicity because its replication in normal cells is highly attenuated. G207 has been used as an antineoplastic agent for the treatment of brain tumors in both preclinical models and clinical trials. 4 -9 We have demonstrated two mechanisms for the antitumor activity elicited by G207: a local oncolytic effect and a systemic antitumor effect mediated by T-cell responses to specific tumor antigens. In a brain metastasis model with human breast tumors in athymic mice, intratumoral inoculation with G207 selectively destroyed metastatic brain tumors, but not the surrounding normal brain tissue. 6 In this model, which uses a human xenograft, tumor regression involves viral oncolytic activity. In contrast, in models with bilaterally established syngeneic tumors in immunocompetent mice, G207 inoculation of one tumor inhibited the growth of both the inoculated and the distant, noninoculated tumors. 10 Unlike the situation in athymic mice, tumor growth inhibition in immunocompetent mice involves the induction of an antitumor T-cell response. 10 -13 These observations suggested that treatment of local tumors with G207 affects distant metastatic tumors through the induction of a specific immune response against tumor antigens.
In 20 -40% of patients with cancer, the primary cancer will metastasize to the brain. 14 -16 This percentage has been increasing over the last two decades, partly because of the increased survival of cancer patients. Metastases to the brain frequently result in severe and debilitating neurological complications, including paralysis, seizures, and impaired cognition. The conventional treatment for metastatic brain tumors is surgical resection followed by radiation and chemotherapy, and in some instances radiosurgery. 17, 18 Some metastatic brain tumors recur despite these treatments, and the prognosis for these patients does not substantially improve. 19 Thus, the development of novel strategies for the treatment of metastatic brain tumors is required.
Here we propose a novel therapeutic approach for the treatment of metastatic brain tumors, involving a combination of oncolytic viral therapy and cancer vaccination using a replication -conditional mutant of HSV, G207. Genetic modification of tumor cells has been shown to stimulate an effective immune response against tumors outside the CNS. Immunization with murine colon adenocarcinoma CT26 cells transfected with the gene coding for the hemagglutination antigen of influenza virus produced systemic antitumor immunity against tumor challenge in the cecum, liver, and lungs, but not in the brain. 20 Although a significant antitumor effect was elicited against distant CT26 tumors in the skin and liver by the inoculation with G207 of subcutaneous ( s.c. ) CT26 tumors as an in situ cancer vaccine, 21 only a limited antitumor effect was observed against tumors in the brain. 22 In these mice, specific cytotoxic T lymphocyte (CTL ) responses were induced not only against HSV but also against the tumor antigen. In this study, we demonstrated that intratumoral inoculations with G207 of both intracranial ( i.c. ) and s.c. tumors significantly enhanced the therapeutic effect of the in situ cancer vaccine on metastatic brain tumors through viral modification of the brain tumor and both anti-HSV and antitumor T cells.
Materials and methods

Cell lines
CT26 cells, derived from mouse colon adenocarcinoma (H-2 d ), 23 and P815 cells, derived from mouse mastocytoma ( H -2 d ), 24 were cultured in Dulbecco's minimum essential medium (DMEM ) containing 10% heat -inactivated fetal calf serum (IFCS ) and penicillin -streptomycin. Meth A cells, from a mouse fibrosarcoma ( H -2 d ) 25 ( kindly provided by Dr H Ikeda, Mie University, Japan ), were maintained in RPMI 1640 containing 10% IFCS, 50 M 2 -mercaptoethanol, 2 mM glutamine, 20 mM HEPES (N 0 -2-hydroxyethylpiperazine -N 0 -2 -ethanesulfonic acid ) buffer, and penicillin -streptomycin.
Virus
The construction of G207 has been described. 4 It contains deletions in both copies of the ICP34.5 gene, and an E. coli lacZ insertion that inactivates the ICP6 gene. African green monkey kidney cells ( Vero cells; ATCC, Rockville, MD ) were maintained in DMEM with 10% IFCS and penicillinstreptomycin. Virus was propagated in Vero cells at a multiplicity of infection ( MOI ) of 0.01 at 348C.
Intracerebral tumor therapy
All animal procedures were approved by the Keio University School of Medicine Animal Care and Use Committee. The animals were 6 -to 8 -week -old BALB / c or BALB /c (nu / nu) females. For surgical procedures, each mouse was anesthesized with an intraperitoneal (i.p. ) injection of a 0.25-to 0.30 -mL solution consisting of 84% bacteriostatic saline, 10% sodium pentobarbital ( 50 mg /mL ), and 6% ethyl alcohol.
An experimental model of brain metastasis was developed with CT26 cells or both CT26 and P815 cells in BALB /c mice. Stereotactic injection of 1Â10 4 tumor cells was performed at a point 1 mm rostal of the bregma, 2 mm right of midline, and 2 mm deep from the skull surface in the right frontal lobe, followed by s.c. injection of 5Â10 5 tumor cells in the back of the same mouse (day 0 ). In mice harboring both i.c. and s.c. tumor cells, G207 was injected into either the i.c. tumor ( 1Â10 6 pfu ), the s.c. tumor (1Â10 7 pfu ), or both at day 5. A second injection of G207 (1Â10 7 pfu) into the s.c. tumor was performed at day 8. Mock -infected extract, prepared from mock -infected Vero cells, was used as a control for the virus inoculum. The s.c. tumor was removed 15 days after tumor implantation and the animals were followed until death. Mice that survived for longer than 100 days were rechallenged in the contralateral brain and skin with 1Â10 4 and 5Â10 5 CT26 tumor cells, respectively. To generate effector cells, some mice were sacrificed and their spleens harvested 15 days after first virus inoculation. For pathological studies, animals were sacrificed and perfused with 2% paraformaldehyde in phosphate -buffered saline. Brains were isolated, fixed in 10% neutral -buffered formalin, and embedded in paraffin. Sections (10 m) were cut and mounted on gelatin -coated slides. The mounted brain sections were stained with hematoxylin and eosin.
Effector cells
Single -cell suspensions of splenocytes from individual mice treated with G207 or mock inoculum were cultured in RPMI 1640 medium with 10% IFCS, 50 M 2 -mercaptoethanol, 2 mM glutamine, 20 mM HEPES, and penicillin -streptomycin in 24-well plates at a concentration of 3Â10 6 cells /mL. As stimulators, 1Â10 6 CT26 or G207 -infected Meth A cells were added to the medium after inactivation with 200 g /mL mitomycin C. Before the coculture, the Meth A cells were infected with G207 at an MOI of 10 pfu / cell overnight, and the G207 was inactivated by incubation at 568C for 15 minutes. 26 Effector cells were harvested after 7-8 days of in vitro culture.
51
Cr release assay Four-hour 51 Cr release assays were performed as previously described. 10 Peptide AH1, the nonamer SPSYVYHQF, is the immunodominant antigen derived from the envelope protein ( gp70 ) of an endogenous ecotropic murine leukemia virus ( MuLV ) and presented by the major histocompatibility
Cancer Gene Therapy
Immuno-viral therapy of brain tumors M Toda et al complex ( MHC ) class I L d molecule. 27 H-2L d -restricted peptide P815AB, LPYLGWLVF, is the immunodominant antigen derived from murine mastocytoma P815 cells. 28 Before labeling, Meth A cells were pulsed with 1 g/mL L drestricted peptides AH1 or P815AB for 1 hour. For the preparation of HSV-infected target cells, Meth A cells were infected with G207 at an MOI of 10 overnight and the viruses were inactivated by heating to 568C for 15 minutes. 26 The target cells labeled with 50 Ci of Na 51 CrO4 ( 51 Cr ) were mixed with effector cells for 4 hours at the effector-totarget ratios indicated. The amount of 51 Cr release was determined with a -counter, and the percent -specific lysis was calculated from triplicate samples as follows: [ (experimental cpm À spontaneous cpm )/ (maximum cpm À spontaneous cpm ) ]Â100. (Fig 1 ) . Histological evaluation revealed that all the mice died from the brain tumor. A control animal that did not receive any virus had a large tumor mass clearly visible in the right hemisphere at 34 days postimplantation of CT26 cells (Fig 2A ) . Mice treated with only an i.c. intratumoral injection of G207 ( 1Â10 6 pfu ) did not show prolonged survival and died within 40 days, with a median survival time of 27.2 days ( Fig 1 ) . Mice treated with only s.c. intratumoral injections of G207 (1Â10 7 pfu ) showed a prolonged survival ( P< .05; Wilcoxon test ), with a median survival time of 34.3 days ( Fig 1) . However, the therapeutic efficacy of the s.c. intratumoral inoculations with G207 was limited, and only one mouse survived for 100 days. That mouse died from an operation to rechallenge it with CT26 tumors, and no tumor was detected in the brain.
To determine whether G207 induced a tumor-specific CTL response, the antigen specificity of T cells generated in vitro from splenocytes was tested in a 51 Cr release assay. No specific CTL response against either CT26 or G207 -infected Meth A cells was detected in the mock -inoculated mice ( data not shown ). G207 injection into i.c. tumors also did not induce a CTL response against either CT26 or HSV ( Fig 3,  A and B ). This result suggests that i.c. intratumoral inoculation with G207 may involve a direct oncolytic activity of G207. In contrast, G207 injections into s.c. tumors induced specific CTL responses against both HSV and CT26 (Fig 4, A and B ). This result indicates that the therapeutic efficacy of s.c. intratumoral inoculation with G207 may involve induced systemic immune responses. However, a strong antitumor effect was not observed in metastatic brain tumors.
A significant antitumor effect of the combined i.c. and s.c.
G207 treatment on metastatic brain tumors
In contrast to inoculation with G207 into either the i.c. or s.c. tumor alone, the combined treatment using both i.c. and s.c. Five days after tumor implantation, G207 was injected into either the i.c. tumors, s.c. tumors, or both. At day 8, the G207 injection into the s.c. tumor was repeated. Mockinfected extract, prepared from mock -infected Vero cells, was used as a control for the virus inoculum. The s.c. tumor was removed 15 days after tumor implantation and the animals were followed until death. Mice that received the i.c. intratumoral inoculation with G207 did not show a prolonged survival ( n = 9 ). In contrast, the survival of mice that received the s.c. intratumoral inoculations with G207 was significantly greater than that of mock -treated mice ( n = 16, P < .05, Wilcoxon test ). Mice that received the combined treatment, both i.c. and s.c. intratumoral inoculations with G207, survived significantly longer than mice treated with an s.c. intratumoral inoculation alone ( n = 13, P < .05, Wilcoxon test ). Long -term survivors after the combined treatment were rechallenged with injections into the contralateral brain and skin of 1Â10 4 and 5Â10 5 CT26 tumor cells, respectively, at day 100 or 150 after the first tumor implantation. These mice survived for an additional 100 days or more without evidence of tumors.
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Immuno-viral therapy of brain tumors M Toda et al intratumoral inoculations provided a strong antitumor effect on metastatic brain tumors. In BALB /c mice, 1Â10 4 CT26 cells were injected into the right frontal lobe and 5Â10 5 CT26 cells into the skin on day 0. G207 was then injected into the i.c. and s.c. tumors at day 5 and into the s.c. tumor alone at day 8. A significant prolongation in survival was observed in mice that received the combined treatment (Fig  1 ) . Seven of the 13 mice (53.8% ) survived for longer than 100 days, with a median survival time of 147.2 days. These mice were rechallenged in the contralateral brain and skin with 1Â10 4 and 5Â10 5 CT26 tumor cells, respectively, at day 100 or 150 after the first tumor implantation. They survived an additional 100 days or more without evidence of tumor. These results indicate that the combined treatment provided efficient and long -term antitumor immune protection against metastatic brain tumors.
For the histological examination, we sacrificed representative mice that had received the combined treatment 34 days after implanting the CT26 cells. We observed hyaline change without any obvious tumor mass at the site of tumor cell implantation in the right hemisphere (Fig 2B ) . Examination of the brain from one of the long -term survivors, sacrificed 130 days after tumor rechallenge, revealed the operation scar without any tumor mass in the left hemisphere ( Fig 2C ) or elsewhere in the brain.
To determine whether the combined treatment induced a tumor-specific CTL response, the antigen specificity of the T cells generated in vitro from splenocytes was tested in a 51 Cr release assay. Specific CTL responses against CT26 as well as AH1, a tumor antigenic peptide for CT26, but not P815AB, a tumor antigenic peptide for P815, were induced in mice that had received the combined treatment ( Fig 3A ) . The combined treatment also induced a CTL response against HSV (Fig 3B ) . Similarly, specific CTL responses against CT26 and HSV were induced in mice treated with s.c. intratumoral inoculations with G207 (Fig 4, A and B ) . No significant difference was observed in the CTL response against CT26 or HSV between the mice receiving the combined treatment and those receiving s.c. intratumoral inoculations with G207 alone.
Lack of antitumor effect of the combined treatment in athymic mice
To evaluate the potential role of T cells in the combined treatment, the antitumor effect of the treatment was evaluated in athymic BALB / c mice. Mice treated with mock inoculations died within 20 days, with a median survival time of 17.8 days. No prolongation in survival was observed in mice that received the combined treatment, with 
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Involvement of anti -HSV immunity in the significant antitumor effect of the combined treatment
To evaluate whether anti -HSV T-cell responses are critical for induction of the significant antitumor effect observed with the combined treatment, we examined the efficacy of the treatment on another model of metastatic brain tumor. CT26 tumor cells were injected into the brain of BALB / c mice (1Â10 4 cells ) and 5Â10 5 P815 tumor cells were injected into the skin (i.c. CT26 and s.c. P815), or CT26 tumor cells were injected into both sites ( i.c. and s.c. CT26 ). G207 was then injected into both the i.c. and s.c. tumors 5 days later and again into the s.c. tumor at day 8. As seen in the other model, survival was significantly prolonged in mice implanted with i.c. CT26 and s.c. P815 cells (Fig 6 ) . Three of the seven mice ( 43% ) survived for longer than 100 days, with a median survival time of 139.3 days. There was a complete response in 60% of the mice implanted with i.c. and s.c. CT26 cells to this combined treatment, with a median survival time of 162.4 days. No statistical difference was observed in the survival times between these two models. Because there seemed to be no T-cell cross -reactions between CT26 and P815 cells ( Fig 3A ) , the therapeutic efficacy in the mice implanted with i.c. CT26 and s.c. P815 cells may not involve antitumor T cells. Thus, the antitumor effect of the combined treatment appeared to depend on the viral modification of the brain tumor and the induced anti -HSV immune response.
Discussion
Because of the BBB, which restricts immune cell entry into the CNS, and the lack of a lymphatic system, which limits the release of antigen from the CNS, 29 CNS -derived antigens are not easily accessible to immune cells. Thus, it may be difficult to evoke immune responses against primary CNS tumors. In the case of metastatic brain tumors, however, the primary tumors exist outside the CNS and may stimulate the immune system. Once activated, T cells may reach the metastatic tumors in the brain. In our experiments, however, the antitumor effect of s.c. intratumoral inoculation with G207 as an in situ cancer vaccine was less against tumors in the brain than against tumors in liver or skin, 21, 22 although specific CTL responses to the tumor antigen were induced in the spleen. Similarly, it has been reported that immunization with CT26 cells expressing the hemagglutination antigen of influenza virus produces systemic antitumor immunity in various tissues, but not in the brain. 20 Recent reports indicate that brain -derived gangliosides exert inhibitory effects on T cells. 30, 31 These observations suggest that the immunolog- Cr release assay. The injection of G207 into i.c. tumors alone did not induce a significant CTL response against either CT26 ( A ) or HSV ( B ). In contrast, CTL responses were induced against CT26 as well as the CT26 tumor antigenic peptide ( AH1 ), but not the P815 tumor antigenic peptide ( P815AB ), in mice that received the combined treatment ( A ). The combined treatment also induced a CTL response against HSV ( B ). Bars represent mean ± SEM of three mice per group.
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Immuno-viral therapy of brain tumors M Toda et al ical environment in the CNS is significantly different from that outside of the CNS. The murine colorectal carcinoma cell line, CT26, has been widely used as a syngeneic tumor model to study immunotherapy. 27, 32, 33 In normal mice, CT26 is poorly immunogenic: 10 3 -10 4 cells can cause a lethal tumor and do not induce detectable tumor-specific CTLs. 32, 34 The peptide AH1 derived from the envelope protein ( gp70 ) of MuLV has been identified as the immunodominant MHC class Irestricted antigen for CT26. 27 It has been suggested that anti-AH1 -specific CTLs have a significant role in CT26 tumor rejection because adoptive transfer of the peptidespecific CTL line was able to cure established s.c. CT26 tumors. Therefore, the poorly immunogenic murine colo- Five days after tumor implantation, G207 or a mock preparation was injected into both the i.c. and s.c. tumors. At day 8, the G207 injection into the s.c. tumor was repeated. The s.c. tumor was removed 15 days after tumor implantation and the animals were followed until death. No prolonged survival was observed in mice given the combined treatment ( n = 8 ) compared with the mock treatment ( n = 6 ).
Immuno-viral therapy of brain tumors M Toda et al rectal carcinoma CT26, expressing an identified tumor antigen, was used to investigate the efficacy of G207 in this metastatic brain tumor model. The injection of G207 into i.c. tumors induced neither systemic anti-HSV nor antitumor CTL responses, suggesting that this antitumor effect depends on the viral oncolytic activity (Fig 7 ) . Although HSV-1 infects a wide variety of human cell types, many rodent tumor cell types are resistant to HSV-1 infection. G207, a highly attenuated mutant of HSV-1, is further restricted in its host range, unable to replicate in most murine or rat tumor cells. CT26 cells, derived from one of the murine tumors susceptible to G207, are efficiently destroyed by G207 at an MOI of 1 but not 0.1 pfu/cell in vitro. 10 Infection at an MOI of 1 reflects the Figure 6 Involvement of anti -HSV immunity in the significant antitumor effect of the combined treatment. Tumor cells were injected into the brain ( 1Â10 4 CT26 cells ) and skin ( 5Â10 5 P815 cells ) of BALB / c mice ( i.c. CT26 and s.c. P815 ), or CT26 tumor cells were injected into both sites ( i.c. and s.c. CT26 ) on day 0. Five days after the tumor implantation, G207 was injected into both the i.c. and s.c. tumors. At day 8, the G207 injection into the s.c. tumor was repeated. The s.c. tumor was removed 15 days after tumor implantation and the animals were followed until death. The survival time in mice implanted with i.c. CT26 and s.c. P815 ( n = 7, P < .005, Wilcoxon test ) and i.c. and s.c. CT26 ( n = 5, P = .011, Wilcoxon test ) and given the combined treatment with G207 was significantly prolonged. There was no significant difference in survival times between these two models. 
Immuno-viral therapy of brain tumors M Toda et al inherent cytotoxicity of the virus, whereas infection at an MOI of 0.1 requires active viral replication and the spread of progeny virus for significant cytotoxicity to occur. 6 Therefore, in this model, no apparent therapeutic effect could be elicited by i.c. intratumoral inoculation with a relatively low dose of G207. Previous studies have shown that the antitumor effect in immune -competent mice with syngeneic tumors involves the induction of an antitumor immune response. 10 -13 G207 inoculation of s.c. tumors induced specific CTL responses to HSV as well as the tumor antigen AH1, the immunodominant MHC class I-restricted antigen for CT26. 27 However, it is still unclear as to what mechanisms induce tumor-specific CTLs after the s.c. intratumoral inoculation with G207. Local HSV infection of the tumor may attract circulating antigen -presenting cells (APCs ) that take up tumor antigens and activate CD8 + T cells. 27 A subset of APCs can process exogenous antigens into the MHC class I pathway and present them to CD8 + T-cell clones. 35, 36 Released tumor antigens from virally destroyed tumor cells may be picked up by APCs, carried to the draining lymph nodes, and presented to T cells. Strong T-cell responses against HSV may help activate relatively weak T-cell responses against the tumor through the secretion of a variety of cytokines and the induction of costimulatory and adhesion molecules on APCs. In mice that received a s.c. intratumoral inoculation with G207, the antitumor effect against metastatic brain tumors involves the induced antitumor immune responses (Fig 7 ) . The s.c. intratumoral inoculation with G207 showed a significant, but limited, therapeutic efficacy against tumors in the brain, possibly due to inhibitory factors to T cells in the CNS. Despite the apparent limitations imposed on the CNS immune system, inflammatory responses develop within the brain following a variety of stimuli. 37 HSV-infected tumor cells in the brain may be good targets for anti-HSV T cells induced by s.c. intratumoral inoculation with G207. HSV infection in the brain causes local inflammation, which may disrupt the BBB and attract immune cells, including antitumor T cells. Viral infection of the brain tumor significantly enhanced the therapeutic efficacy of the s.c. intratumoral inoculation with G207. In the combined treatment, direct viral oncolytic activity, antitumor T cells, and anti -HSV T cells seem to be involved in the antitumor effect against metastatic brain tumors ( Fig 7) . Our results in athymic mice and in the model using two different tumors ( Figs 5 and 6) suggest that anti -HSV T-cell responses may be important for induction of the significant antitumor effect of the combined treatment.
For a successful clinical application of this therapeutic approach, various host -virus interactions, particularly immune responses, need to be considered. By adulthood, 60 -90% of the population is seropositive for HSV-1. 38 Preexisting and therapeutically elicited immune responses to the virus may cooperate to enhance the efficacy of the combined treatment. Conversely, an elicited immune response would limit viral replication and minimize the therapeutic oncolytic activities of G207. G207 is currently being used in a clinical trial for the treatment of recurrent glioma. 39 So far, i.c. inoculation of G207 at doses up to 3Â10 9 pfu has caused neither acute toxicity, viral shedding, nor clinically evident delayed reactivation of the virus. These reassuring observations support the possibility of using G207 for the treatment of metastatic brain tumors.
